Chloroquine as a Modulator of T Cell Immune Activation

HIV Clinical Trial

Official title:

Chloroquine as a Modulator of T Cell Immune Activation to Improve CD4 Recovery in HIV-infected Participants Receiving Antiretroviral Therapy: A Proof-of-concept Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02004314
• Other study ID #: CTN 246
• Status: Completed
• Phase: N/A
• First received: November 27, 2013
• Last updated: December 3, 2013
• Start date: October 2009
• Est. completion date: March 2012

Study information

• Verified date: December 2013
• Source: CIHR Canadian HIV Trials Network
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Canadian Institutes of Health Research
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the effect of chloroquine in individuals infected with HIV. Researchers will aim to determine if chloroquine treatment in participants whose viral loads are suppressed on combination antiretroviral therapy (ART), results in improved immune activation and CD4 cell recovery.

The study will recruit 20 individuals and will last approximately 44 weeks. Eligible participants will receive an oral dose of chloroquine (250 mg) once daily from week 8 through week 32. All participants will be asked to have rectal biopsy samples (week 0 and week 32) to study T cell immune activation in the mucosa rectal site.

Description:

Clinical data has identified chloroquine as a potential modulator of immune activation. The study's dose of chloroquine is the same as the dose recommended for patients having autoimmune diseases. In these autoimmune cases, a daily dose of chloroquine at 250 mg for 12 weeks has shown improvement in symptoms and decreases in inflammatory cytokines synthesis and a reduction in TLR -mediated immune activation. Study findings could help provide information about where and under what circumstances chloroquine treatment may reduce T cell activation and help restore circulating CD4 T cells.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 19
• Est. completion date: March 2012
• Est. primary completion date: January 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Documented HIV infection by Western Blot, EIA assays or viral load assay.

• Aged between 18 and 65 years.

• Viral load less than 50 copies per ml for at least the previous 36 weeks.

• CD4 cell count less than or equal to 350 cells per litre.

• On stable ART

• Vital signs, physical examination and laboratory results do not exhibit evidence diseases such as advanced cirrhosis or advanced liver

• Karnofsky performance status greater than or equal to 80 per cent.

• Participant does not require and agrees not to take, for the duration of the study, any medication that is contraindicated with chloroquine.

• Able to give informed consent.

Exclusion Criteria:

• Active AIDS events in the last 3 months

• Co-infection with active hepatitis B or C virus.

• Current use or use within four weeks prior to the baseline visit, of cytotoxic agents, systemic corticosteroids or any immuno-modulatory agents.

• Current use within four weeks prior to the chloroquine therapy the following medications: methadone, chlorpromazine, cimetidine, cyclosporin, methotrexate and penicillanime.

• Psychiatric or cognitive disturbance or illness that could preclude compliance with the study.

• Patient with clinically significant hemophilia and Von-Willebrand disease and any severe bleeding disorder.

• Experimental HIV immune based therapy within 6 months of screening visit.

• Allergic reaction to chloroquine.

• A history of retinitis or any retinal problem.

• Subjects with G6PD deficiency, porphyria, psoriasis, cirrhosis, hearing deficiency (including tinnitus), myopathy and cardiomyopathy.

• Pregnant and breast-feeding women.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• HIV

Intervention

Drug:
• Chloroquine

Locations

Country	Name	City	State
Canada	Montreal Chest Institute, McGill University Health Centre	Montreal	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
CIHR Canadian HIV Trials Network

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The expression of CD38 on CD8 circulating T cells	To assess whether the expression of CD38 on CD8 circulating T cells will be reduced and whether circulating CD4 T cell recovery will be enhanced after 24 weeks of chloroquine treatment in adults whose HIV replication is suppressed by ART.	44 weeks, with 8 weeks observation period on ART alone to assess stability of activated CD8CD38 T cells, followed by 24 weeks chloroquine treatment with ART and a 12-week follow-up period on ART alone	No
Secondary	Safety of chloroquine treatment measured by adverse events, hematology and serum chemistries and Amsler grid test.	Safety of chloroquine treatment measured by adverse events, hematology and serum chemistries and Amsler grid test	44 weeks, with 8 weeks observation period on ART alone to assess stability of activated CD8CD38 T cells, followed by 24 weeks chloroquine treatment with ART and a 12-week follow-up period on ART alone	Yes